Interojo Inc. (KOSDAQ:119610)
14,240
-520 (-3.52%)
Oct 29, 2026, 3:30 PM KST
Interojo Revenue
Interojo had revenue of 29.45B KRW in the quarter ending June 30, 2026, a decrease of -6.02%. This brings the company's total for the last twelve months to 124.14B, up 12.83% year-over-year. In the year 2025, Interojo had annual revenue of 118.44B with 2.24% growth. That makes Interojo the 23,136th largest company in the world by revenue and 1,303rd in South Korea.
Revenue (ttm)
124.14B
Revenue Growth
+12.83%
P/S Ratio
1.29
Revenue / Employee
165.97M
Employees
748
Market Cap
159.96B
Revenue by Geography
- Asia 58.41B 49.3%
- Europe 26.33B 22.2%
- South Korea 19.78B 16.7%
- Other 13.25B 11.2%
- North America 663.78M 0.6%
Fiscal year ended Dec 31, 2025 See the full Interojo breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 118.44B | 2.60B | 2.24% |
| Dec 31, 2024 | 115.84B | -3.46B | -2.90% |
| Dec 31, 2023 | 119.30B | 1.48B | 1.25% |
| Dec 31, 2022 | 117.82B | 10.29B | 9.57% |
| Dec 31, 2021 | 107.53B | 19.33B | 21.92% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.12T |
| Celltrion | 4.90T |
| Samsung Epis Holdings | 1.51T |
| Chong Kun Dang Holdings | 961.64B |
| Daewon Pharmaceutical | 614.64B |
| ALTEOGEN | 254.01B |
| JW Lifescience | 253.71B |
| Samil Pharmaceutical Co.,Ltd | 207.33B |